ArticleAtherosclerosis plus2025
Association of uric acid with all-cause mortality in acute coronary syndrome patients with T2DM.
Article in Atherosclerosis plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The specific prognostic value of hyperuricemia for all-cause mortality in patients with concurrent type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS) remains unclear, particularly regarding the modifying effect of glycemic control status (HbA1c levels). This study elucidated the uric acid (UA)-mortality association in ACS patients with T2DM and examined this relationship across different HbA1c subgroups. Methods and results: The study included 2265 ACS patients with T2DM who were assigned to four groups based on UA quartiles. During a median follow-up period of 4.4 years, 203 all-cause deaths occurred. Significant positive associations were found in patients with HbA1c level above 7 (Quartile 1 group: Hazard Ratio (HR): 3.215, 95 % confidence interval (CI): 1.525-6.780, p = 0.002; Quartile 3 group: HR: 2.725, 95 % CI: 1.308-5.678, p = 0.007; Quartile 4 group: HR: 3.369, 95 % CI: 1.644-6.905, p = 0.001). Interaction analysis between UA quartiles and HbA1c subgroups showed no statistical significance (p-interaction = 0.648). Restricted cubic splines revealed a J-shaped relationship between UA and all-cause mortality. Kaplan-Meier analysis demonstrated higher event-free survival rates in the Quartile 2 group (log-rank test: p < 0.001). Conclusions: A J-shaped curve characterizes the association between UA levels and all-cause mortality in patients with T2DM and ACS. Patients with an appropriate UA level exhibited better prognosis. Post-hoc analyses revealed stronger point estimates for the prognostic effect of UA in patients with suboptimal glycemic control, although interaction testing did not achieve statistical significance. Further studies with larger subgroup samples are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.